Quintiles Global Commercial Solutions opens in Brazil

Thursday, July 19, 2012 02:36 PM

To help biopharmaceutical companies enter the rapidly growing Brazilian biopharmaceutical market, Quintiles has opened its Global Commercial Solutions business in Brazil, offering customized sales forces, market penetration strategies and product solutions.

The move into Brazil is part of Quintiles' strategy to help biopharma companies expand into growing emerging markets while managing costs and risk. Quintiles recently expanded the business into Russia and into the Middle East and North Africa (MENA) region. Brazil is the world's fifth most populous country, with a population of about 205 million and a biopharmaceutical market valued at $17.1 billion.

Leading the business in Brazil will be general manager Vera Valente, based in Sao Paulo. Most recently, Valente was a director at Interfarma (the Brazilian Pharmaceutical Research Companies Association), where she was responsible for the innovation program and the market access group.

"Brazil is an increasingly important and growing commercial market, and we're eager to help our customers enter this market in a way that manages risks and increases the probability of success," said James Featherstone, senior vice president of global commercial solutions for Quintiles.

"Brazil undoubtedly represents a huge untapped opportunity for the biopharmaceutical industry,” said Valente. “However, as with any new market, there are challenges.”

 

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs